Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab
- 1 November 2009
- journal article
- case report
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 22 (s1), S16-S18
- https://doi.org/10.1111/j.1529-8019.2009.01266.x
Abstract
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatmentKeywords
This publication has 9 references indexed in Scilit:
- Extensive psoriasis induced by pegylated interferon: a case reportJournal of Medical Case Reports, 2007
- Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with EtanerceptJournal of Investigative Dermatology, 2005
- The role of T cells in psoriasisJournal of the European Academy of Dermatology and Venereology, 2003
- Adalimumab (a fully human anti-tumour necrosis factor monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trialsAnnals Of The Rheumatic Diseases, 2002
- PegylationClinical Pharmacokinetics, 2001
- Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis CPublished by Oxford University Press (OUP) ,2000
- Interferon-lnduced Psoriasis in a Patient with Chronic Hepatitis CDermatology, 1993
- Psoriasis-Exazerbation bei Therapie mit α-InterferonDeutsche Medizinische Wochenschrift (1946), 1989
- PSORIASIS AND ALPHA-INTERFERONThe Lancet, 1986